File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chemotherapy for early-stage gastrointestinal lymphoma

TitleChemotherapy for early-stage gastrointestinal lymphoma
Authors
Issue Date1991
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy And Pharmacology, 1991, v. 27 n. 5, p. 385-388 How to Cite?
AbstractA total of 176 patients with gastrointestinal lymphomas were reviewed. According to a modified staging classification, 51 of them had stage I/II disease and the remaining 125 had stage III/IV disease. In most cases (68%), the histology was intermediate-grade according to the NIH working formulation, and the B-cell immunophenotype was involved in 89% of the 45 cases with a known immunophenotype. The primary site was the stomach in 56% of cases and the bowel in 44%. A significantly higher proportion (P = 0.001) of those with bowel lymphomas had stage III/IV disease (88% vs 57%). The primary gastrointestinal lesion was resected in 122 patients, including all 51 cases of stage I/II disease. In all, 8 stage I/II patients were given radiotherapy alone following surgery and the other 43 underwent chemotherapy; of the latter, 19 received additional radiotherapy following chemotherapy. Chemotherapy was also given to 112 stage III/IV patients, 42 of whom underwent additional radiotherapy. Factors associated with a poorer prognosis included advanced disease, bowel lymphoma and advanced age. Although the complete response (CR) rate according to disease stage was similar, stage I/II patients receiving chemotherapy showed a significantly lower relapse rate, better disease-free survival following CR and improved survival as compared with those receiving radiotherapy alone. However, additional radiotherapy following chemotherapy did not further improve the clinical outcome.
Persistent Identifierhttp://hdl.handle.net/10722/161895
ISSN
2015 Impact Factor: 2.824
2015 SCImago Journal Rankings: 1.283
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_US
dc.contributor.authorChiu, Een_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorChoy, Den_US
dc.contributor.authorLoke, SLen_US
dc.date.accessioned2012-09-05T05:15:53Z-
dc.date.available2012-09-05T05:15:53Z-
dc.date.issued1991en_US
dc.identifier.citationCancer Chemotherapy And Pharmacology, 1991, v. 27 n. 5, p. 385-388en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttp://hdl.handle.net/10722/161895-
dc.description.abstractA total of 176 patients with gastrointestinal lymphomas were reviewed. According to a modified staging classification, 51 of them had stage I/II disease and the remaining 125 had stage III/IV disease. In most cases (68%), the histology was intermediate-grade according to the NIH working formulation, and the B-cell immunophenotype was involved in 89% of the 45 cases with a known immunophenotype. The primary site was the stomach in 56% of cases and the bowel in 44%. A significantly higher proportion (P = 0.001) of those with bowel lymphomas had stage III/IV disease (88% vs 57%). The primary gastrointestinal lesion was resected in 122 patients, including all 51 cases of stage I/II disease. In all, 8 stage I/II patients were given radiotherapy alone following surgery and the other 43 underwent chemotherapy; of the latter, 19 received additional radiotherapy following chemotherapy. Chemotherapy was also given to 112 stage III/IV patients, 42 of whom underwent additional radiotherapy. Factors associated with a poorer prognosis included advanced disease, bowel lymphoma and advanced age. Although the complete response (CR) rate according to disease stage was similar, stage I/II patients receiving chemotherapy showed a significantly lower relapse rate, better disease-free survival following CR and improved survival as compared with those receiving radiotherapy alone. However, additional radiotherapy following chemotherapy did not further improve the clinical outcome.en_US
dc.languageengen_US
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshCombined Modality Therapyen_US
dc.subject.meshFemaleen_US
dc.subject.meshGastrointestinal Neoplasms - Drug Therapy - Pathology - Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshLymphoma - Drug Therapy - Pathology - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshPrognosisen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSurvival Rateen_US
dc.titleChemotherapy for early-stage gastrointestinal lymphomaen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/BF00688862-
dc.identifier.pmid1998998-
dc.identifier.scopuseid_2-s2.0-0026012819en_US
dc.identifier.volume27en_US
dc.identifier.issue5en_US
dc.identifier.spage385en_US
dc.identifier.epage388en_US
dc.identifier.isiWOS:A1991EZ41300009-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridChiu, E=24827833600en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridChoy, D=8663654500en_US
dc.identifier.scopusauthoridLoke, SL=7006559512en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats